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Abstract
Aim. To demonstrate clinical effectiveness of micronized palmitoylethanolamide-trans-
polydatin combination in reducing endometriotic chronic pelvic pain. Other endometri-
otic-pains were also assessed.
Methods. Systematic reviews of PubMed, SCIELO, Scopus, and AJOL. Randomized 
trials and observational studies reporting a visual analogue scale for pain or similar in 
endometriotic patients were reviewed. A mean improvement of visual analogue scale (or 
visual analogue scale-like) scores at enrollment and at a three-month follow-up was as-
sessed and interpreted clinically.
Results. Four studies of poor quality were available. In a heterogeneous sample of 
endometriotic patients with pain, the administration of micronized palmitoylethanol-
amide/trans-polydatin (400 mg/40 mg) twice a day for three months provided a clini-
cally relevant improvement of chronic pelvic pain and dysmenorrhea while improving 
deep dyspareunia to a limited degree. No clinically relevant improvement was found for 
dyschezia.
Conclusion. More studies are warranted for assessing the drugs-related efficacy.
INTRODUCTION
Endometriosis affects women’s health throughout life 
[1]. With a prevalence of 10% [2], Oppelt et al. [3] es-
timated in-patient treatment costs of endometriosis in 
Germany for 2006 at € 40 708 716. As endometriosis 
is a painful syndrome [4, 5] and a common cause of 
chronic pelvic pain [6-8], considerable therapeutic ef-
forts have been directed to treat endometriosis-associ-
ated pain. Chronic pelvic pain in endometriosis is also 
associated with mood disorders, thereby affecting pa-
tient quality of life [9, 10].
Current treatments for endometriotic pain include 
hormonal therapies (levonorgestrel-releasing intra-
uterine systems, progestagens, estroprogestinic pills, 
aromatase inhibitors, gonadotropin-releasing hormone 
agonists), cyclooxygenase-2 inhibitors, and non-steroi-
dal anti-inflammatory drugs (NSAIDs) [5]. Surgical 
intervention represents another option for treating pain 
in endometriosis [5]. However, potential side effects 
linked to the chronic use of pharmacological therapies 
and risks of surgical approaches hamper the effective-
ness of such interventions, especially in terms of achiev-
ing long-lasting pain relief. Clearly, today’s therapies for 
managing endometriosis leave much space for improve-
ment [11, 12] and for the development of more effec-
tive drugs for treating endometriotic pain [12, 13].
Endometriosis and inflammation are intricately 
linked to one another [14]. Inflammatory processes are 
regulated by mast cells [15-17] which are found close 
to nerve fibers in endometriotic lesions [18, 19]. Con-
ceivably, mast cell activation may contribute to pain 
development and hyperalgesia in endometriotic lesions 
during inflammation [18-21]. Targeting mast cells could 
thus prove useful for controlling inflammation while 
providing pain relief in endometriosis [22].
Palmitoylethanolamide (PEA) is a member of the N-
acylethanolamine family of fatty acid amides. It is a sig-
naling molecule which is able to down modulate mast 
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cell activation and microglial cell behaviors [23-25]. It 
acts peripherally on the crosstalk between mast cells 
and nociceptive nerve fibers, and in the central nervous 
system by reducing central pain hypersensitization as-
sociated with the activation of microglia [26, 27]. Trans-
polydatin (PO) is a precursor of resveratrol. Resveratrol 
has been shown to bring about regression of endome-
triotic lesions in experimental models of endometriosis 
[28], a likely consequence of its strong anti-angiogenic 
and anti-inflammatory actions [29].
Clinical studies in which PEA/PO was used to treat 
endometriosis were first published in 2010 [30, 31] and 
suggested that a combination of micronized PEA/PO is 
effective on chronic pelvic pain due to endometriosis. In-
draccolo et al. [30] reported only 4 cases of endometrio-
sis treatment with oral micronized PEA/PO (400 mg/40 
mg) twice a day for three months, while Cobellis et al. 
[31] treated 18 patients in one arm of a randomized trial 
with micronized PEA/PO (200 mg/20 mg) orally, three 
times a day for three months. Both studies showed an 
improvement in mean pain visual analogue scale (VAS) 
scores for chronic pelvic pain and other endometriotic 
pains (with improvement in the micronized PEA/PO 
arm versus placebo arm in the randomized trial [31]). 
The above observations were substantiated by results of 
VAS score improvement in a study on 610 patients [32] 
treated with micronized PEA (600 mg twice a day) for 
chronic pain due to several causes, leading us to specu-
late that micronized PEA is effective also on chronic 
pelvic pain, even in the presence of endometriosis.
Although pre-clinical studies and the few clinical ob-
servations have suggested that the micronized PEA/PO 
combination is effective on pain in endometriosis, some 
questions come to mind regarding this new pharmaco-
logical treatment:
How effective is the combination of micronized PEA/
PO on endometriotic chronic pelvic pain? To answer the 
question, one should assess improvements in VAS (or 
VAS-like) scores. This matter was evaluated by Jensen 
et al. [33], who demonstrated that a reduction in VAS 
scores between 35% and 40% (20-30 mm) would be 
considered of clinical relevance;
To what extent is the micronized PEA/PO combina-
tion clinically effective on other acute pains of endo-
metriosis? While there is a reasonable expectation for 
the miconized PEA/PO combination to be effective on 
chronic pelvic pain, the effectiveness of the micronized 
PEA/PO on other acute pains in patients with endome-
triosis remains unclear;
Does the combination of micronized PEA/PO have 
a different behavior in sub-groups of patients (age, dis-
ease stage, previous surgery, other therapies, other co-
morbidities, etc.)? 
Finally, can the micronized PEA/PO combination 
modify the natural history of endometriosis? By block-
ing both inflammation and pain, treatment could mod-
ify evolution of the disease.
The current meta-analysis was carried out principally 
to address the question as to whether or not micronized 
PEA/PO combination is therapeutically effective on 
endometriosis-related chronic pelvic pain. The second-
ary aims will be covered as the data permit.
METHODS
The meta-analysis has been registered on the Inter-
national Prospective Register of Systematic Reviews 
(PROSPERO), CRD 42015024671. Electronic re-
sources and library availability were provided by the 
Sapienza University of Rome, if not freely available 
online. The present systematic review was prepared by 
searching (up to 19 July 2015) PubMed, Scopus, AJOL 
(African Journal online), and SCIELO, using the fol-
lowing key-words: “palmitoylethanolamide” AND “en-
dometriosis”, “palmitoylethanolamine” AND “endome-
triosis”, “PEA” AND “endometriosis”, “polydatin”AND 
“endometriosis”, “impulsin” AND “endometriosis”, “im-
pulsine” AND “endometriosis”. Impulsin is the older 
name of PEA [34]. No language limit or time frame 
limit was set.
The bibliographic search yielded 46 references from 
only Scopus and PubMed. After removing duplicates, 
the references list was reduced to 13. Observational 
studies and randomized trials enrolling patients with 
endometriosis and endometriosis-related pain who were 
treated with a combination of micronized PEA/PO were 
considered eligible for meta-analysis. The patients must 
have had a pain assessment (VAS or VAS-like) before 
starting treatment and at least the same pain assessment 
during follow-up. No limits were placed on VAS assess-
ment (in particular, no differences between the milli-
metric or centimetric assessment of VAS). Studies with 
VAS-like assessments were also considered for inclusion. 
Based on such criteria, seven studies were eliminated. 
The remaining six studies [30, 31, 35-38] were also ex-
amined for other relevant citations, but none were found. 
The study of Lo Monte’ et al. [36] was not considered 
because of possible case duplication. Further, the report 
from Cobellis et al. [31] was excluded, as it was the only 
study with micronized PEA/PO (200 mg/20 mg) admin-
istered three times a day for three months. Assuming 
that pain relief is dose-dependent, the latter results can-
not be incorporated in the current meta-analysis. We 
were thus able to consider for meta-analysis four studies 
[30, 35, 37, 38] with five effect sizes.
A stringent (albeit subjective) quality score was ap-
plied to the cited studies, and ranged from + to 4+. The 
score considered four key items: sample homogeneity, 
sample number, availability of data, and clarity in pre-
sentation. The perfect study should be scored 16+, with 
a minimum limit for quality of 8+. Even poor quality 
studies were included in meta-analysis, provided that 
they were able to satisfy at least one of the questions 
listed at the end of the introduction section.
Figure 1 schematically summarizes the bibliographic 
search and study selection. The outcome variable was 
the mean VAS (or numeric rating scale, NRS) reduction 
after a three months treatment (delta). For the sake of 
stringency, VAS (or NRS) score improvements were ex-
pressed in centimeters. It is possible to express a pain 
value of 10 (like 10 cm or 100 mm) for NRS or VAS, 
because the two have been reported to be about equiva-
lent [39-41], even if NRS produces more variability [41].
Missing data were requested of corresponding au-
thors. If corresponding authors were unable to provide 
missing data, they were recalculated or estimated. To 
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estimate the delta, we referred to the Lipsey et al. rules 
[42] which imply that standard errors of each delta 
should be estimated by using already known coefficients 
of correlation. The latter are calculated from VAS values 
at enrollment and at the three-month follow-up. There-
fore, at least one pool of raw data is needed to calculate 
coefficients of correlation. As such, only raw data from 
Indraccolo et al. [30] are available for meta-analysis, al-
though they are too few to estimate reliable coefficients 
of correlation. In order to obtain a more reliable pic-
ture of the mean VAS reductions, authors of the cited 
studies [35, 37, 38] were asked to provide means and 
standard deviations (or variances or standard errors), 
calculated on the distribution of delta values. Cobel-
lis et al. [35] were unable to provide these data, while 
Di Francesco et al. [38] provided mean and standard 
deviation of the delta distribution on 9 patients (ex-
cluding a patient who had become pregnant before the 
three-month follow-up), together with missing data on 
dyschezia. Additionally, Giugliano et al. [37] provided 
means and standard deviations for the VAS reduction 
distributions (deltas) of their two groups. For the Co-
bellis et al. [35] study, mean effect sizes were estimated 
from medians according to Hozo et al. [43], while vari-
ances were estimated from ranges according to Boyles 
[44] (Median Moving Range Estimator). Ranges and 
medians were extracted from histograms.
Standard errors were obtained by estimating the co-
efficients of correlation already cited. Coefficients of 
correlation were re-calculated from standard deviations 
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Figure 1
Flow-chart of the phases of study selection.
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in Di Francesco et al. [38] and Giugliano et al. (two 
samples) [37] following Lipsey rules [42]. Mean coef-
ficients of correlation (weighted for the numerosity of 
the three samples) were used to estimate missing stan-
dard errors in Cobellis et al. [35] for chronic pelvic pain, 
dysmenorrhea and deep dyspareunia.
Positive, negative and equivocal findings for endome-
triotic pain in each study were assessed according to 
Jensen et al. [33]. To be more stringent, a 95% lower 
confidence interval of more than 3 cm of VAS (or NRS) 
improvement was considered clinically relevant (posi-
tive finding), while a 95% higher confidence interval of 
VAS (or NRS) improvement of less than 2 cm was tak-
en as no clinical improvement (negative finding). Any 
mean improvement with a lower or higher 95% con-
fidence interval encompassing or crossing the 2-3 cm 
range was considered equivocal because of some degree 
in clinical improvement (equivocal finding).
Fixed models were used for calculating mean effects 
sizes. Heterogeneity among studies was checked by us-
ing Q-statistic. Heterogeneity, when found, was tested 
by examining if studies with higher VAS (or NRS) val-
ues at enrollment had higher VAS reductions (partition-
ing the effect size variance) [42]. Statistical significance 
was set at p < 0.05.
RESULTS
Table 1 summarizes the characteristics of the four 
studies included in the meta-analysis and reports results 
of quality assessment. Only the studies of Cobellis et 
al. [35] and Indraccolo et al. [30] reached the minimal 
limit for quality. The ability of each study to answer the 
four questions specified in the introduction is also re-
ported in Table 1. All studies answered the first question 
(improvement in chronic pelvic pain) while the meta-
analysis was able to partially assess the effect of mi-
cronized PEA/PO treatment on the other acute pains 
of endometriosis (deep dyspareunia, dysmenorrhea, 
dyschezia). Sub-group analysis was not possible (reply 
to third question), nor is the meta-analysis able to as-
sess the capability of micronized PEA/PO to modify the 
evolution of endometriosis (reply to fourth question).
The study by Indraccolo et al. [30] is the only one for 
which raw data are fully available, thereby no missing 
values must be estimated. While full data availability re-
sulted in data reliability and adequacy for meta-analysis, 
it is necessary to note that data have been collected on 
a very limited number of patients (n = 4). VAS improve-
ments are reported as graphical trends and, for chronic 
pelvic pain, also as mean and standard deviation. How-
ever, there is a mistake in the authors’ reporting, as 
the graphical trend and text report for chronic pelvic 
pain are not congruent. Additionally, results exposi-
tion is poor and inaccurate. Further, Indraccolo et al. 
[30] does not provide follow-up data after three months 
twice daily oral treatment with micronized PEA/PO 
(400 mg/40 mg). Reduction in analgesic consumption 
and changes in sonographic patterns of endometriosis 
were also reported.
Cobellis et al. [35] is a randomized, double-blind, 
three-arm study, designed to prove the superiority of 
400 mg/40 mg of micronized PEA/PO orally, twice a 
day for three months versus celecoxib and placebo. The 
micronized PEA/PO arm (21 patients) was able to be 
meta-analyzed after wide estimation of missing values. 
Diagnosis of endometriosis was made by laparoscopy 
according to 2005 ESHRE guidelines [4]. Patients had 
stage I and II endometriosis. The authors reported re-
sults at enrollment and after three months follow-up as 
medians and ranges as histograms for chronic pelvic 
pain, deep dyspareunia, dysmenorrhea. Self-assessed 
satisfaction for therapy was reported, but information 
about long-term follow-up and improvement in instru-
mental patterns of endometriosis was lacking.
Giugliano et al. [37] present an observational, non-
randomized, two-arm study, designed to demonstrate 
that orally administered 400 mg/40 mg micronized 
PEA/PO twice a day for three months is differentially 
effective in reducing VAS scores in patients with recto-
vaginal endometriosis (group A, 19 cases) versus those 
with ovarian endometriosis (group B, 28 cases). There 
were no differences between the two groups. Diagnosis 
of endometriosis was made by laparoscopic examina-
tion, according to 2005 ESHRE guidelines [4]. We can-
not exclude that some patients who underwent laparos-
copy then received surgical therapy. Data are reported 
in tabular form as means and standard deviations at 
enrollment and at each month of follow-up. Long-term 
follow-up and instrumental improvements of endome-
triosis were not reported. Both groups A and B were 
meta-analyzed, and each group was considered as a 
single effect size.
Di Francesco et al. [38] is a randomized, open-label, 
three-arm study intended to show the effectiveness 
of 400 mg/40 mg micronized PEA/PO (orally, twice 
a day for six months, given to 10 patients at enroll-
ment) in controlling the painful symptoms associated 
with endometriosis in comparison to gonadotropin 
releasing hormone agonist (GnRh) and estroproges-
tinic pill. An 11-point NRS (0-10) was used for pain 
assessment. Endometriosis (stage II and III) was diag-
nosed laparoscopically with patients required to have 
at least a pain value ≥ 5 (deep dyspareunia, dysmenor-
rhea, dysuria, chronic pelvic pain and, perhaps, other 
kinds of pain related with endometriosis). Results were 
reported in tabular form at enrollment and graphically 
as trends in means and standard errors for six-month 
follow-up. During the study period one patient in the 
micronized PEA/PO group dropped out because of 
pregnancy. This study reported on quality of life (SF12 
inventory) but lacked information on long-term follow-
up and instrumental improvements of the disease. The 
protocol description and results in Di Francesco et al. 
[38] are confusing. The micronized PEA/PO arm of the 
Di Francesco et al. [38] study was incorporated in the 
meta-analysis without the pregnant patient (9 cases).
The meta-analysis encompassed 81 patients. For 
deep dyspareunia and for dysmenorrhea, 80 cases were 
assessed. For dyschezia, 60 cases were assessed. The 
mean effect sizes fall into one of three categories: posi-
tive, equivocal and negative, in accord with clinical sig-
nificance assigned to VAS reduction (Table 2) [33].
Figure 2 depicts a Forest plot for chronic pelvic pain, 
with data reported as mean reductions in VAS (or 
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Table 1
Study characteristics
Study characteristics Indraccolo et al.  
[30]
Giugliano et al.  
[37]
Cobellis et al.  
[35]
Di Francesco et al. 
[38]
Study type Small series Two- arm, prospective, 
observational study
Three- arm, randomized, 
double-blind, clinical trial
Three-arm, 
randomized, open-
label, clinical trial
Number of patients 4 patients 
(mean age 34.3 ± 9.78)
2 clinical and 
sonographic diagnoses, 
2 post-surgery 
diagnoses
47 patients
Post-surgery diagnoses.
Group A: 19 patients with 
recto-vaginal endometriosis
(mean age 36.7 ± 5.2).
Group B: 28 patients with 
ovarian endometriosis (mean 
age 34.6 ± 6.5)
21 patients in the PEA/
PO arm, aged between 
26 and 37.
Post-surgery diagnoses.
Stages I and II 
endometriosis
10 patients in the PEA/
PO arm (mean age 33.9 
± 1.61)
Post-surgery diagnoses
Stages II and III 
endometriosis.
1 drop-out for 
pregnancy during 
therapy
Main objective Chronic pelvic pain 
reduction from 
enrollment to three 
months follow-up. 
Patients observed 
monthly
Check differences in pain 
reduction between two arms 
from enrollment to three 
months
Patients observed monthly
Superiority of PEA/PO 
versus placebo and 
celecoxib (200 mg twice 
a day for 7 days for three 
months)
Patients observed at 
three months follow-up
Non-superiority 
of PEA/PO versus 
leuprorelin 11.25µg 
(single administration) 
and ethinyl-estradiol-
drospirenone pill 
0.03 mg/3 mg for six 
months
Patients observed 
monthly
Pain assessment 100 mm VAS 10 cm VAS 10 cm VAS 11 points NRS
Other therapies 1 patient: pill and 
NSAIDs
3 patients: NSAIDs
Group A
13 patients: pill
6 patients: NSAIDs
Group B
18 patients: pill
10 patients: NSAIDs
Not reported Not reported
Side effects Nausea Not reported Not found Not found
Pain assessed
Chronic pelvic pain
Dysmenorrhea
Deep dyspareunia
Dyschezia
Dysuria
Means (± st deviations) 
VAS at enrollment
78 (± 13) mm
38 (± 19) mm§
81 (± 31) mm§
42 (± 34) mm
42 (± 40) mm§
Means (± st deviations) VAS at 
enrollment   
A                     B
5.8 (± 2.8) cm    4.6 (± 2.4) cm
6.5 (± 2.1) cm   6.9 (± 1.6) cm
4.1 (± 3.3) cm  3.7 (± 2.9) cm
4.1 (± 3.4) cm  1.6 (± 2.1) cm
/                        /
Medians (and ranges) 
VAS at enrollment
7.6 (8.2-6.5) cm
7.8 (8.8 -6.6) cm
7.4 (8.4-6.1) cm
/
/
Means (± st errors) NRS 
at enrollment*
5.3 (± 1.12)
7.5 (± 0.7)
5 (± 1.07)
0.8 (± 0.80)
1.2 (± 0.63)
Secondary findings Reduction of analgesic 
consumption
Improvement in 
sonographic patterns 
of endometriosis
Improvement of  pain scores 
in both arms through months
(no differences between two- 
arm pain improvement)
Improvement of self-
reported satisfaction for 
therapy
Improvement in quality 
of life (SF-12 inventory)
Quality assessments
-Homogeneity of sample
-Numerosity of sample
-Availability of data
-Clarity in the exposure 
of the study (objectives, 
experimental design, 
results)
+
+
++++#
++
+
++
+++
+
++
++
+
+++
+
+
++
+
Data availability to meet 
objectives of meta-analysis
1) Clinically relevant 
reduction of chronic pelvic 
pain
2) Clinically relevant 
reduction of other 
endometriosis pain 
3) Sub-group analyses
4) Natural history of the 
disease
++++
++++
+
+
++++
+++
+++
/
++++
+++
/
/
++++
+++
/
/
# This score was given because all raw data of this study are available to the meta-analysts.
§Data from three patients.
*Values extracted from the Di Francesco et al. published article – 10 cases [38].
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NRS) scores and 95% confidence intervals. Micron-
ized PEA/PO (400 mg/40 mg), given orally twice a day 
for three months, reduced VAS score by 4.10 cm at the 
three-month follow-up. This improvement is clinically 
relevant (95% CI 3.75-4.45 cm, p < 0.01, Q = 39.16, 
p < 0.01 for four degrees of freedom, indicating het-
erogeneity). Heterogeneity was resolved by partition-
ing the variance between two groups (higher and lower 
VAS or NRS at enrollment). Greater reductions were 
found in studies [30, 35] with higher VAS scores at 
enrollment.
Figure 3 depicts a Forest plot for dysmenorrhea. 
Data are reported as mean reductions of VAS (or NRS) 
scores and 95% confidence intervals. Micronized PEA/
PO (400 mg/40 mg), given orally twice a day for three 
months, reduced by 3.68 cm the VAS score at three 
months follow-up. This reduction is clinically relevant 
(95% CI 3.33-4.03 cm, p < 0.01; Q = 15.94, p < 0.05 
for four degrees of freedom, indicating heterogeneity). 
Heterogeneity was resolved by partitioning variance be-
tween the two groups (higher and lower VAS or NRS at 
enrollment). Greater reductions were found in studies 
[35, 38] with higher VAS scores at enrollment.
Data for deep dyspareunia are depicted as a Forest 
Figure 2
Forest plot for chronic pelvic pain. The horizontal lines define 
the interval to retain VAS improvements of some clinical rel-
evance.
Table 2
Positive, negative and equivocal findings
Study Improvement not 
clinically relevant:
(negative finding)
Improvement of some 
clinical relevance:
(equivocal finding)
Improvement clinically 
relevant
(positive finding)
Chronic 
pelvic pain
Indraccolo et al. [30] X
Giugliano et al., A [37] X
Giugliano et al., B [37] X
Cobellis et al. [35] X
Di Francesco et al. [38] X
Dysmenorrhea Indraccolo et al. [30] X
Giugliano et al., A [37] X
Giugliano et al., B [37] X
Cobellis et al. [35] X
Di Francesco et al. [38] X
Deep 
dyspareunia
Indraccolo et al. [30] X
Giugliano, A [37] X
Giugliano, B [37] X
Cobellis et al. [35] X
Di Francesco et al. [38] X
Dyschezia Indraccolo et al. [30] X
Giugliano et al., A [37] X
Giugliano et al., B [37] X
Di Francesco et al. [38] *  X*
Results from the Di Francesco et al. [38] study are on nine patients.
*This effect size can be added because Di Francesco provided unpublished data on the three-month follow-up for dyschezia.
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plot in Figure 4, and reported as mean reductions of 
VAS (or NRS) scores and 95% confidence intervals. Mi-
cronized PEA/PO (400 mg/40 mg), given orally twice 
daily for three months reduced by 3.18 cm the VAS 
score at three-month follow-up. It is unclear if this re-
duction is always clinically relevant (95% CI 2.71-3.65 
cm, p < 0,01; Q = 14.63; p < 0.05 for four degrees of 
freedom, indicating heterogeneity). Heterogeneity 
was resolved by partitioning variance between the two 
groups (higher and lower VAS or NRS at enrollment). 
Greater reductions were found in studies with higher 
VAS scores at enrollment [30, 35].
Figure 5 depicts a Forest plot for dyschezia. Data are 
reported as mean reductions of VAS (or NRS) scores 
and 95% confidence intervals. Micronized PEA/PO 
(400 mg/40 mg), administered orally twice a day for 
three months, reduced by 0.67 cm the VAS score at 
three-months follow-up. Although this difference was 
statistically significant, VAS reduction was not clinically 
relevant (95% CI 0.38-0.96 cm, p < 0.01, Q = 15.25 p < 
0.05 for three degrees of freedom, indicating heteroge-
neity). Heterogeneity was not resolved by partitioning 
the effect size variance among two groups (higher and 
lower VAS or NRS at enrollment).
Because results are provided encompassing the esti-
mates from Cobellis et al. [35], we also provide results 
without use of such estimates (Table 3).
DISCUSSION
This meta-analysis demonstrates that, in a hetero-
geneous sample of endometriotic patients with endo-
metriosis-related pain, the combination of micronized 
PEA/PO (400 mg/40 mg) administered orally twice a 
day for three months produces a clinically significant 
reduction in chronic pelvic pain and dysmenorrhea and 
a more modest, but significant reduction, in deep dys-
pareunia. No clinically significant reduction was found 
for dyschezia. 
These results are drawn from poor quality studies, 
which do not report the rate of respondents. This makes 
not possible to gather information concerning clinically 
relevant improvement at patient’s level. Therefore, the 
alleged drugs’ efficacy could be only presumed by the 
mean effect that the micronized PEA/PO had on treated 
patients. It is conceivable that in a heterogeneous popu-
lation of endometriotic patients, some could respond to 
Figure 3
Forest plot for dysmenorrhea. The horizontal lines define the 
interval to retain VAS improvements of some clinical relevance.
Figure 4
Forest plot for deep dyspareunia. The horizontal lines define 
the interval to retain VAS improvements of some clinical rel-
evance.
Figure 5
Forest plot for dyschezia. The horizontal lines define the inter-
val to retain VAS improvements of some clinical relevance.
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therapy with robust reductions in VAS scores, while oth-
ers fail to respond – thus leading to the observed mean 
VAS improvement. Another possibility is that the ma-
jority of endometriotic patients with pain improve their 
pain perceptions in a clinically significant way, thereby 
producing the mean VAS reduction. Accordingly, as sug-
gested by sensitive analysis, the best responders should 
be patients with higher values of VAS (or NRS) scores 
at enrollment. Such behavior can be expected from any 
pain-killer drug. Concerning chronic pelvic pain, VAS 
improvement agreed with reports in other large samples 
of patients with chronic pain (mostly neuropathic pain) 
treated with only micronized PEA [32, 45]. Therefore, 
it is likely that micronized PEA exerts its main effective-
ness on chronic pelvic pain, rather than PO. Addition-
ally, it is likely that PEA is more effective than placebo, 
as suggested by the randomized trials of Cobellis et al. 
[31, 35], which are in agreement with the findings of the 
large randomized trial of Guida et al. [45].
It is unclear if the improvement in VAS for all acute 
pains of endometriosis can be attributed to the im-
provement in chronic pelvic pain. It cannot be excluded 
that PEA, by acting on peripheral and central sensitiza-
tion mechanisms [46-48] in chronic pain prevents wors-
ening of acute pain over the long-term. However, PO 
may, in part, also contribute to the observed therapeutic 
effectiveness. Addressing these issues and quantifying 
the percentage of respondents (efficacy) will neces-
sitate studies on sub-groups of endometriotic patients 
with VAS scores at enrollment ≥ 5 cm for acute pains 
and without clinically significant chronic pelvic pain.
The present meta-analysis fails to investigate changes 
in the natural course of endometriosis, as a follow-up of 
more than 6 months was not reported. Improvements 
in VAS scores have been reported from enrollment to 
six-month follow-up [38] and evidence for improve-
ment in instrumental patterns of endometriosis is sug-
gested [30]. However, these findings are too limited to 
permit speculation on changes in the natural history of 
endometriosis.
Studies on the combination of micronized PEA/PO 
for treatment of endometriosis reported in databases 
other than PubMed, AJOL, SCIELO and Scopus were 
not investigated. This limitation may introduce a degree 
of bias in our meta-analysis. However, meta-analyzed 
studies used same kind of 400 mg/40 mg micronized 
PEA/PO combination. Micronized PEA/PO combina-
tion is provided by an Italian manufacturer. It is cur-
rently unlikely that the same micronized 400 mg/40 mg 
PEA/PO was used in studies eventually published in 
other countries than Italy. 
CONCLUSION
In conclusion, in a heterogeneous sample of patients 
with endometriotic pains, the 400 mg/40 mg combina-
tion of micronized PEA/PO, given orally twice a day 
for three months should be considered a promising 
treatment for the relief of endometriosis-associated 
pain. Confirmation of these initial findings will require 
randomized, double-blind, placebo-controlled clinical 
trials of sufficient power to assess rates of respondents 
in sub-groups of patients, in order to fully appreciate 
the efficacy of micronized PEA/PO combination as a 
therapy for endometriosis, together with cohort studies 
to assess long-term effects of such therapy.
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